Brief: Blueprint Medicines Reports First Quarter 2023 Results
04/05/2023 12:06
Blueprint Medicines Corp BPMC.O :
* BLUEPRINT MEDICINES REPORTS FIRST QUARTER 2023 RESULTS
* BLUEPRINT MEDICINES CORP - RAISING 2023 AYVAKIT NET
PRODUCT
REVENUE GUIDANCE TO $135 MILLION TO $145 MILLION FOR ADVANCED SM
AND GIST
* BLUEPRINT MEDICINES - AYVAKIT NET PRODUCT REVENUES 2023
GUIDANCE
EXCLUDES REVENUE FROM ANTICIPATED AYVAKIT INDICATION EXPANSION
IN ISM IN MID-2023
Source text for Eikon: ID:nPn7q7ty9a
Further company coverage: BPMC.O
Recent news on Blueprint Medicines
See all newsBrief: Sanofi Announces Extension Of Blueprint Tender Offer
Brief: Blueprint Medicines Announces Data Reinforcing Safety Profile Of Long-Term Ayvakit
U.S. STOCKS ON THE MOVE-Texas Instruments, Broadcom, Circle
UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal
U.S. RESEARCH ROUNDUP-Biomea Fusion, GE Aerospace, P&G